Published in J Neurol Sci on April 01, 1977
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest (2002) 1.36
Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res (2014) 0.90
Interferon beta and glatiramer acetate therapy. Neurotherapeutics (2013) 0.90
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2011) 0.89
Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol (1996) 0.87
Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. J Cent Nerv Syst Dis (2012) 0.84
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
Glatiramer in the treatment of multiple sclerosis. Int J Nanomedicine (2006) 0.78
Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2007) 0.76
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. J Neurol (1996) 0.76
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Anti-influenza response achieved by immunization with a synthetic conjugate. Proc Natl Acad Sci U S A (1982) 1.85
Chemical characterization and subunit structure of human N-acetylhexosaminidases A and B. Biochemistry (1976) 1.84
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci U S A (1971) 1.67
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A (2000) 1.52
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res (1975) 1.48
On the existence of suppressor cells. Int Arch Allergy Immunol (1993) 1.46
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
Chemically defined antiviral vaccines. Annu Rev Microbiol (1980) 1.41
Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol (1979) 1.40
Acute upper gastrointestinal bleeding in Jerusalem 1988-91: causes, characteristics and relation to nonsteroidal anti-inflammatory drugs. Isr J Med Sci (1993) 1.40
Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40
Seasonal fluctuations in acute upper gastrointestinal bleeding: lack of effect of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol (1992) 1.39
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol (1998) 1.38
Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38
Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc Natl Acad Sci U S A (1976) 1.37
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate. Proc Natl Acad Sci U S A (1969) 1.32
Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin. Proc Natl Acad Sci U S A (1984) 1.32
Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci (1984) 1.30
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol (1996) 1.30
Antibodies to papain. A selective fractionation according to inhibitory capacity. Biochemistry (1967) 1.30
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun (1993) 1.29
Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex. FEBS Lett (1970) 1.27
Antibodies against synthetic peptides of the B subunit of cholera toxin: crossreaction and neutralization of the toxin. Proc Natl Acad Sci U S A (1983) 1.26
Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A (1982) 1.26
T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol (1993) 1.25
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol (1974) 1.24
Synthetic vaccines. J Immunol Methods (1983) 1.23
Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity. Infect Immun (1988) 1.23
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol (1973) 1.17
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci U S A (1988) 1.17
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol (1973) 1.17
Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch Neurol (1979) 1.16
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A (1999) 1.16
Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16
Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol (1996) 1.15
In vivo effects of antibodies against a high frequency idiotype of anti-DNA antibodies in MRL mice. J Immunol (1984) 1.15
The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Res (1975) 1.15
A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine (2009) 1.14
Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. Proc Natl Acad Sci U S A (1986) 1.14
Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-association and soluble antigen. Nature (1977) 1.13
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A (1992) 1.11
Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol Lett (1998) 1.11
Chemical and immunological characterization of a unique antigenic region in lysozyme. Biochemistry (1971) 1.11
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A (1999) 1.11
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs. J Exp Med (1975) 1.10
Synthetic approaches to vaccines for infectious and autoimmune diseases. Vaccine (1992) 1.09
Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem (1990) 1.09
Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci (1978) 1.09
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol (1994) 1.08
Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine (1996) 1.08
Experimental allergic encephalomyelitis--susceptibility and suppression. Immunol Rev (1981) 1.08
In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev (1982) 1.08
Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine (1992) 1.07
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
A selective fractionation of anti-lysozyme antibodies of different determinant specificities. Eur J Biochem (1968) 1.06
Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect Immun (1999) 1.05
Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry (1976) 1.05
[Strain-dependent differences in the specificity of antibody responses toward lysozyme]. J Immunol (1971) 1.04
Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature (1991) 1.03
Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A (1975) 1.03
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
A simple fluorescent method to determine complement-mediated liposome immune lysis. J Immunol Methods (1977) 1.02
Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol (1982) 1.02